These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 22125404)

  • 1. Challenges in the clinical measurement of ocular surface disease in glaucoma patients.
    Pflugfelder SC; Baudouin C
    Clin Ophthalmol; 2011; 5():1575-83. PubMed ID: 22125404
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prevalence of ocular surface disease in glaucoma patients.
    Leung EW; Medeiros FA; Weinreb RN
    J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Understanding Ocular Surface Disease in Glaucoma: A Comparative Analysis of Symptoms and Objective Parameters.
    Romano J; Ferreira N; Godinho G; Tomás R; Oliveira N; Sousa JP
    Cureus; 2024 Feb; 16(2):e54070. PubMed ID: 38481920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ocular surface disease incidence in patients with open-angle glaucoma.
    Radenković M; Stanković-Babić G; Jovanović P; Djordjević-Jocić J; Trenkić-Božinović M
    Srp Arh Celok Lek; 2016; 144(7-8):376-83. PubMed ID: 29652117
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prevalence of ocular surface complaints in Brazilian patients with glaucoma or ocular hypertension.
    Costa VP; Marcon IM; Galvão Filho RP; Malta RF
    Arq Bras Oftalmol; 2013; 76(4):221-5. PubMed ID: 24061832
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Ocular Surface Disease Treatment in Patients with Glaucoma.
    Mylla Boso AL; Gasperi E; Fernandes L; Costa VP; Alves M
    Clin Ophthalmol; 2020; 14():103-111. PubMed ID: 32021074
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ocular surface disease and glaucoma: how to evaluate impact on quality of life.
    Rossi GC; Pasinetti GM; Scudeller L; Bianchi PE
    J Ocul Pharmacol Ther; 2013 May; 29(4):390-4. PubMed ID: 23215770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ocular surface alterations and topical antiglaucomatous therapy: a review.
    Actis AG; Rolle T
    Open Ophthalmol J; 2014; 8():67-72. PubMed ID: 25317218
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Prevalence of Ocular Surface Disease Among Glaucoma Patients in Thailand.
    Ruangvaravate N; Prabhasawat P; Vachirasakchai V; Tantimala R
    J Ocul Pharmacol Ther; 2018 Jun; 34(5):387-394. PubMed ID: 29596033
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence of Ocular Surface Disease and Associated Risk Factors in Glaucoma Patients: A Survey Study of Ophthalmologists.
    Yıldırım N; Bozkurt B; Yüksel N; Ateş H; Altan-Yaycıoğlu R; Ocakoğlu Ö; Burcu A; Yalvaç I; Evren Kemer Ö; Orhan M
    Turk J Ophthalmol; 2022 Oct; 52(5):302-308. PubMed ID: 36317767
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tear film osmolarity in patients treated for glaucoma or ocular hypertension.
    Labbé A; Terry O; Brasnu E; Van Went C; Baudouin C
    Cornea; 2012 Sep; 31(9):994-9. PubMed ID: 22710490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tear Film Osmolarity, Ocular Surface Disease and Glaucoma: A Review.
    Fogagnolo P; Torregrossa G; Tranchina L; Ferreras A; De Cillá S; Labbé A; Figus M; Ottobelli L; Rossetti L
    Curr Med Chem; 2019; 26(22):4241-4252. PubMed ID: 31345142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Managing the ocular surface after glaucoma filtration surgery: an orphan topic.
    Agnifili L; Figus M; Sacchi M; Oddone F; Villani E; Ferrari G; Posarelli C; Carnevale C; Nucci P; Nubile M; Mastropasqua L
    Graefes Arch Clin Exp Ophthalmol; 2024 Jul; 262(7):2039-2056. PubMed ID: 38091058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface.
    Awe OO; Onakpoya OH; Adeoye AO
    Niger Med J; 2020; 61(4):184-188. PubMed ID: 33284876
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ocular surface disease: a known yet overlooked side effect of topical glaucoma therapy.
    Ruiz-Lozano RE; Azar NS; Mousa HM; Quiroga-Garza ME; Komai S; Wheelock-Gutierrez L; Cartes C; Perez VL
    Front Toxicol; 2023; 5():1067942. PubMed ID: 37547228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preservatives and ocular surface disease: A review.
    Kahook MY; Rapuano CJ; Messmer EM; Radcliffe NM; Galor A; Baudouin C
    Ocul Surf; 2024 Aug; 34():213-224. PubMed ID: 39098762
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tear osmolarity measurements in dry eye related to primary Sjögren's syndrome.
    Utine CA; Bıçakçıgil M; Yavuz S; Çiftçi F
    Curr Eye Res; 2011 Aug; 36(8):683-90. PubMed ID: 21780917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical glaucoma therapy and ocular surface disease: a prospective, controlled cohort study.
    Saade CE; Lari HB; Berezina TL; Fechtner RD; Khouri AS
    Can J Ophthalmol; 2015 Apr; 50(2):132-6. PubMed ID: 25863853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corneal and conjunctival sensitivity in patients with dry eye: the effect of topical cyclosporine therapy.
    Toker E; Asfuroğlu E
    Cornea; 2010 Feb; 29(2):133-40. PubMed ID: 19966564
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.